Hematologic and Immunologic Cell & Gene Therapy
The Hematologic and Immunologic Gene and Cell Therapy scientific committee is focused on all aspects of gene and cell therapy for benign hematologic disorders as well as disorders of the innate and adaptive immune system. The scientific portfolio covers ex vivo modified hematopoietic stem cells (HSCs) with viral and non-viral platforms such as lentiviral and adenoviral vectors, RNA, gene addition and editing with genome editing systems. The scientific portfolio also includes marrow conditioning toxicity, and the fate and function of therapeutically modified autologous or allogeneic cells used to treat primary immunodeficiencies and benign hematological disorders.